Problem
Holien-X has now developed your compound into Phase 2 clinical trials. Unfortunately, they are finding a subset of patients which are showing resistance to the drug. They have sequenced these patients, and all have the following nucleotide sequence.
>MutantProtein
atggcgcagaaagaaaacagctatccgtggccgtatggccgccagaccgcgccgagcggc
ctgagcaccctgccgcagcgcgtgctgcgcaaagaaccggtgaccccgagcgcgctggtg
ctgatgagccgcagcaacgtgcagccgaccgcggcgccgggccagaaagtgatggaaaac
agcagcggcaccccggatattctgacccgccattttaccattgatgattttgaaattggc
cgcccgctgggcaaaggcaaatttggcaacgtgtatctggcgcgcgaaaaaaaaagccat
tttattgtggcgctgaaagtgctgtttaaaagccagattgaaaaagaaggcgtggaacat
cagctgcgccgcgaaattgaaattcaggcgcatctgcatcatccgaacattgaacgcctg
tataactatttttatgatcgccgccgcatttatctgattctggaatatgcgccgcgcggc
gaactgtataaagaactgcagaaaagctgcacctttgatgaacagcgcaccgcgaccatt
atggaagaactggcggatgcgctgatgtattgccatggcaaaaaagtgattcatcgcgat
attaaaccggaaaacctgctgctgggcctgaaaggcgaactgaaaattgcggattttggc
tggagcgtgcatgcgccgagcctgcgccgcaaaaccatgtgcggcaccctggattatctg
ccgccggaaatgattgaaggccgcatgcataacgaaaaagtggatctgtggtgcattggc
gtgctgtgctatgaactgctggtgggcaacccgccgtttgaaagcgcgagccataacgaa
acctatcgccgcattgtgaaagtggatctgaaatttccggcgagcgtgccgatgggcgcg
caggatctgattagcaaactgctgcgccataacccgagcgaacgcctgccgctggcgcag
gtgagcgcgcatccgtgggtgcgcgcgaacagccgccgcgtgctgccgccgagcgcgctg
cagagcgtggcg
Holien-X would like to understand what the patient mutant is? Is it a modest mutation or significant? Where on the protein this mutation is occurring? Is it likely to influence compound binding or another aspect of the protein function?